Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Merck & Co., Inc. (MRCK34.SA)

São Paulo - São Paulo Delayed Price. Currency in BRL
Add to watchlist
54.33-0.63 (-1.15%)
At close: 06:51PM BRT
Advertisement
Sign in to post a message.
  • S
    Simon
    Top Trades For January 2022 👀🔥📈 >>

    https://chart-analysis.tools/top-trade-idea
    Bullish
  • M
    Mike
    30 generic drug companies are partnered to produce and sell a low- cost version of Merck's new covid pill. Thoughts?
  • D
    Dennis
    Keytruda with FDA approval for tx of 16 different CA’s, expanding its use among oncology providers. Bless those (and their families) facing this diagnosis
    Bullish
  • D
    Defund-Secret Service
    Have you noticed the senior management departures under Fraiser?
    A CFO as heir apparent is not a good selection for a scientific company!
  • F
    FEDERICO
    I believe the trend up will continue going into the report on Thursday, Feb. 3. which I also believe they will post a huge quarter, beat on revenue and beat on earnings, huge year overall and they will give a great outlook for another big year ahead for revenues and earnings, and continue increase in dividend pay.

    Heading to and ALL TIME HIGH of $100 per share and the Q4 and year end report will be the tailwind needed for MRK to become a great boring holding for at least the next 5 years that will provide great capital gains while getting paid along the way.

    Onward and Upward

    Blessings
  • F
    FEDERICO
    All gaps have been fully close.

    Now is time to build a solid uptrend this year and print and ALL TIME HIGH, going towards that $100 per share mark.

    Great place to park some money waiting to increase capital and getting paid as we wait. And then using that money to buy into some of the oversold and undervalue small cap Bio/Pharma stocks.

    Onward and Upward

    Blessings
  • B
    Brent
    When MRK advertises on the radio for jobs, you know it's time to buy.
  • S
    SushaG
    With MRK’s robust pipeline, cheap stock price and generous dividend it is just a matter of time until Mr Market figures it out and bids the stock price up to higher levels.

    Looking for a rewarding ‘22.
  • R
    Robert
    It appears an incorrect judgement on MRK pill. No danger such as the PFE pill which has a list of medical issues that will certainly cause side effects. If you have high blood pressure and or take statins or other blood thiners you can not take it. No such restrictions for MRK.
  • P
    Peter
    Why would a Dr. prescribe Merck's Covid drug when the Pfizer drug is much more effective?
  • T
    The REAL Chewdog
    Re: India news story--I agree, lots of concerns in a population which continues to grow rapidly.. In addition, one would think MRK upper management would have better pictures stock pictures of the company to supply the press. MERCK letters on some random concrete wall--? Honestly, tell me how high-tech that looks that looks?
  • K
    Kameron
    Small gains until earnings...$90 pt on tipranks
  • h
    himanshu
    India boosts arsenal against COVID-19 with Merck pill, two more vaccines
    Bullish
  • y
    yesman
    France has cancelled its order for Merck & Co's (MRK.N) COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's (PFE.N) competing drug before the end of Jan.
  • R
    Rob
    Year 2000 was $90, now is $78, investors lost money after 22 years, the stock market is a scam
  • T
    Tintin
    The India Covid pill news is something we already know about the pill. Old news. Pill is meant to be taken only for high risk individuals and comes with restrictions.
  • M
    Masterly
    nice run
  • M
    Marvelous
    Merck
    The second biotech stock to contemplate purchasing at the present time is Merck ( MRK 0.19% ). Like AstraZeneca, Merck has had a tremendous year thus far. First, the company's year-to-date total revenue has surged to $35.2 billion, which represents a 15.1% growth rate compared to the year-ago period.

    Merck's oncology segment, headed by its crown jewel Keytruda, was able to grow its year-to-date segment revenue 22.1% over the year-ago period, to $13.8 billion. Strong momentum from each of Keytruda, Lynparza, and Lenvima helped the oncology segment grow its year-to-date revenue by $2.5 billion, which is 54.2% of the company's total year-to-date revenue growth.

    Even with Keytruda accounting for 35.8% of its year-to-date revenue, Merck appears well-prepared for the drug's loss of exclusivity in major markets that will occur in 2028 for a couple of reasons.

    For one, the vaccine segment saw its total year-to-date revenue fly 22% higher compared to the year-ago period, to $7.1 billion. Also, the animal-health segment advanced its revenue by 21.8% year to date against the year-ago period, to $4.3 billion. Simply put, these two segments combined are about as large as the oncology segment and are growing at equally remarkable rates.

    Second, the company just completed its acquisition of Acceleron last month. Through the deal, Merck receives a late-stage pulmonary arterial hypertension drug known as sotatercept that possesses plenty of blockbuster potential. The company also receives 20% to 25% royalties from Bristol Myers Squibb ( BMY 3.87% ) on the anemia drug known as Reblozyl, which has blockbuster potential in its own right.

    Merck's strong operating fundamentals are expected to continue for the foreseeable future, which is evidenced by the analyst forecast of 15% annual earnings growth over the next five years. When weighed against the forward P/E ratio of just 10, Merck boasts an attractive mix of value and growth. Merck's 3.8% dividend yield is also triple the S&P 500's 1.3%, which is yet another reason investors should consider the stock.
    Bullish
  • J
    JGault
    Congrat's to Merck exec team. Looks like a lock to make dogs of the dow list two years in a row
  • E
    Eddie
    Mrk has really been left in the dust by the other pharmaceutical's successes. Time to rethink about moving my investment. Definitely missed the boat with this one.
Advertisement
Advertisement